Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration
- Conditions
- Age-Related (Dry) Macular Degeneration
- Registration Number
- NCT02540148
- Lead Sponsor
- The Eye Machine Canada Inc.
- Brief Summary
Assess the effectiveness of externally applied micro current electrical stimulation on improving the ETDRS visual acuity in subjects with vision loss from dry age-related macular degeneration (AMD)
- Detailed Description
Micro-current electrical stimulation will be used to treat /each eye in a group of subjects with dry AMD. 60 subjects will be randomly divided into two groups. A ratio of 1:3 will be maintained between control and the experimental groups. In the treatment group, subjects will undergo a treatment session to the enrolled eyes daily for three days during week 1, followed by a single treatment session during weeks 2, 14 and 26 with the Nova Oculus device. A second group of subjects will act as the control group. This group will undergo sham treatment at the same treatment intervals with a non-functional Nova Oculus device. ETDRS visual acuity will be performed on all subjects at enrollment prior to each treatment and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the ETDRS visual acuity of subjects with dry AMD will be determined.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Fifty years of age or older
- Male or female
- Best-corrected vision 20/50 to 20/200 for each enrolled eye
- Confirmed diagnosis of dry AMD
- Vision loss attributable to dry AMD
- Subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent
- Any visually significant retinal pathology other than dry AMD
- Previous intravitreal injection
- Seizure disorders
- Previous vitreo-retinal surgery. (ERM, PPV, RD etc)
- Dense cataract
- Eyelid pathology at the treatment sites
- Glaucoma patients with a visual field mean defect of greater than 10dB on Humphrey visual field testing
- Glasses are up to date (prescription <1 year old)
- Any prior electrical micro-stimulation treatment to the eyes
- Poor general health
- Active cancer
- Life expectancy less than 12 months
- Non-ambulatory
- Not considered suitable for participation for any other reason
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Measure the increase in ETDRS visual acuity for those treated with Nova Oculus™ device to control subjects who did not receive active treatment. 26 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Dr. Kevin Parkinson
🇨🇦Coquitlam, British Columbia, Canada
Dr. Kevin Parkinson🇨🇦Coquitlam, British Columbia, Canada